

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 28, No 6

C O N T E N T S

February 20, 2010

Editorials

Epidermal Growth Factor Receptor Biomarkers in Non-Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma

Frances A. Shepherd and Ming-Sound Tsao (see articles on pages 911 and 918) 903

Stereotactic Body Radiation Therapy Versus Wedge Resection for Medically Inoperable Stage I Lung Cancer: Tailored Therapy or One Size Fits All?

Nasser K. Altorki (see editorial on page 907 and article on page 928) 905

Surgery Versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: Who's Down for the Count?

Robert D. Timmerman (see editorial on page 905 and article on page 928) 907

Natural Killer Cell Consolidation for Acute Myelogenous Leukemia: A Cell Therapy Ready for Prime Time?

Michael R. Verneris and Stephan A. Grupp (see article on page 955) 909

Original Reports

THORACIC ONCOLOGY

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Thomas J. Lynch, Taral Patel, Luke Dreisbach, et al (see editorial on page 903 and article on page 918) 911

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer

Shirin Khambata-Ford, Christopher T. Harbison, Lowell L. Hart, et al (see editorial on page 903 and article on page 911) 918

Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer

Inga S. Grills, Victor S. Mangona, Robert Welsh, et al (see editorials on pages 905 and 907) 928

Reduction of Elevated Plasma Osteopontin Levels With Resection of Non-Small-Cell Lung Cancer

Justin D. Blasberg, Harvey I. Pass, Chandra M. Goparaju, et al 936

Phase II Trial of a Trimodality Regimen for Stage III Non-Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study

Godehard Friedel, Wilfried Budach, Juergen Dippon, et al 942

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by the American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 2318 Mill Road, Suite 800, Alexandria, VA 22314.

2010 annual subscription rates, effective September 1, 2009: US and possessions: individual, \$578; single issue, \$40. International: individual, \$802; single issue, \$50. Institutions: Tier 1: \$817 US, \$1,129 Int'l; Tier 2: \$951 US, \$1,262 Int'l; Tier 3: \$1,373 US, \$1,674 Int'l; Tier 4: \$1,513 US, \$1,813 Int'l; Tier 5: contact JCO for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$289; all other countries, \$401. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

Suzanne E. Dahlberg, Alan B. Sandler, Julie R. Brahmer, et al 949

PEDIATRIC ONCOLOGY

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

Jeffrey E. Rubnitz, Hiroto Inaba, Raul C. Ribeiro, et al (see editorial on page 909) 955

BREAST CANCER

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well Tolerated

Brian Leyland-Jones, Ramon Colomer, Maureen E. Trudeau, et al 960

Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial

Catherine Van Poznak, Rosemary A. Hannon, John R. Mackey, et al 967

Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer

Andrew M. Wardley, Xavier Pivot, Flavia Morales-Vasquez, et al 976

HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients

Bent Ejlertsen, Maj-Britt Jensen, Kirsten V. Nielsen, et al 984

Exercise, Tea Consumption, and Depression Among Breast Cancer Survivors

Xiaoli Chen, Wei Lu, Ying Zheng, et al 991

Nodal-Stage Classification in Invasive Lobular Breast Carcinoma: Influence of Different Interpretations of the pTNM Classification

Carolien H.M. van Deurzen, Gabor Cserni, Simonetta Bianchi, et al 999

Migraine History and Breast Cancer Risk Among Postmenopausal Women

Christopher I. Li, Robert W. Mathes, Elizabeth C. Bluhm, et al 1005

HEMATOLOGIC MALIGNANCIES

Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation

Paul J. Martin, George W. Counts Jr, Frederick R. Appelbaum, et al 1011

Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Andrew M. Evens, Laurie H. Sehn, Pedro Farinha, et al 1017

Evaluation of Coronary Artery Disease by Computed Tomography Angiography in Patients Treated for Childhood Hodgkin's Lymphoma

Serhan Küpeli, Tuncay Hazırolan, Ali Varan, et al 1025

Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

Efstathios Kastiris, Ashutosh D. Wechalekar, Meletios A. Dimopoulos, et al 1031

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era

Andrew M. Evens, Kevin A. David, Irene Helenowski, et al 1038

Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

Steven D. Gore, Ivana Gojo, Mikkael A. Sekeres, et al 1047

GENITOURINARY CANCER

Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study

Sami Antoun, Laura Birdsell, Michael B. Sawyer, et al 1054

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, et al 1061

Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE
Kelvin A. Moses, Alan T. Paciorek, David F. Penson, et al 1069

Biology of Neoplasia

The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney, Ryan B. Corcoran, and Jeffrey A. Engelman 1075

e. Diagnosis in Oncology

Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
Elizabeth R. Gerstner, Matthew P. Frosch, and Tracy T. Batchelor e91

Presentation of Extranodal Natural Killer T-Cell Lymphoma, Nasal Type, With Poorly Circumscribed Erythematous Patches
Laura B. Pincus, James L. Zehnder, Isaac M. Neuhaus, et al e94

Primary Gonadal Germ Cell Tumor Associated With Acute Leukemia With Common Cytogenetics
Rashmi Menon, Przemyslaw Twardowski, Stephen J. Forman, et al e96

e. Correspondence

Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma
Saadettin Kilickap, Gagatay Arslan, Soner Senel, et al e99

Reply to S. Kilickap et al
Ahsun Riaz and Riad Salem e100

Endocrine Effects of Aromatase Inhibitors
Per E. Lønning and Mitch Dowsett e101

Reply to P.E. Lønning et al
Francesco Perrone, Ciro Gallo, Emanuela Rossi, et al e103

Central Institutional Review Board—Facilitated Review Metrics Omit Critical Components
Michael S. Katz and Mary L. Smith e105

Reply to M.S. Katz et al
Todd H. Wagner, Christine Murray, Jacquelyn Goldberg, et al e106

Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot Study
Yoshihiro Nishida, Satoshi Tsukushi, Yoji Shido, et al e107

Breast Cancer Pathology Report: In Response to Zurrida et al
Vincenzo Arena, Ilaria Pennacchia, and Arnaldo Carbone e110



Also in This Issue

- Information for Subscribers
- Information for Contributors
- Manuscript Submission Checklist
- Current Abstracts
- Forthcoming Reports

e Diagnosis in Oncology and Correspondence available at www.jco.org